Grifols initiates a new clinical trial in Spain to evaluate the safety and efficacy of a new drug, which has as its base the immunoglobulin Gamunex-C and contains anti-SARS-CoV-2 police anticoagulants plasma donor obtenidos who managed the disease. The drug promotes a protection of immediate effect post-exposure to virus which was especially used as a complement to the vacancy during the temporary phase during the vacancy, informed this Monday the company of hemoderivados. The test, which was initiated in February and will result in first results, isedited by investigators Oriol Mitjà and Bonaventura Clotet, del Hospitaal Duitsers Trias i Pujol de Badalona (Barcelona).
In the same way participant alrededor of 800 individuals asintomáticos and positive of SARS-CoV-2 and test diagnosis, which are administered by live subcutaneous immunoglobulin of Grifols rica anticuerpos front to virus. The immunoglobulin of Grifols, Gamunex-C, in its form for intravenous, intramuscular or subcutaneous administration “has been demonstrated safety and efficacy in the prevention of various infectious diseases“in immunodeficient patients and used since 15 years with this end.
The medicine “could protect “mayors and medical staff, as with immunodeficiencies with which evacuation is not recommended, and help to help contain fractures in places where the evacuation is initiated or if it is not completed. Mitjà has reported that this treatment with the immunoglobulins as a base “proposes a combination of anti-police policies that, in front of the monoclonals, present a diverse mayor which should increase the ability to protect against viruses “.
Conservation facility
The Medical Director of Grifols, Dr. Antonio Páez, stated that “its facility for never-ending conservation and subcutaneous administration” favor the distribution and use of this potential therapy, which could be administered by any medical consultant avoiding the visit to a hospital center. “If it is confirmed its efficacy, New therapy can be administered to people who are positive about antigen testing and PCR in hospitals and primary care sanitation facilities “, he added.
At the end of 2020, Grifols initiates joint ventures with various companies and various health care agencies in the Itac Clinical Clinic to test the efficacy and safety of the anti-SARS-CoV-2 hyperoglobulin immunoglobulin in hospitalized and severe patients, the results will be known during the first half of 2021.